Latent Labs
Protein design models · Health
How they use Nebius AI Cloud
Latent Labs deploys NVIDIA Blackwell B300 GPUs with Nebius for training and inference in its generative molecular-biology models. These models support protein design and drug-discovery research for industry and academic partners. Its March 2026 announcement describes deployment on Nebius’s full-stack AI infrastructure as demand for compute grew. A Nebius representative describes helping the team test Blackwell after it had used H100 GPUs for model training.
Latent Labs reports initial training speedups of 2–3x, exceeding 4x after hardware-specific optimizations for Blackwell. It identifies NVIDIA Blackwell Server Edition GPUs for inference and reports more than 60% faster inference relative to previous-generation chips, shortening timelines for partners using its models in active drug-discovery programs.
CEO Simon Kohl describes a compute-diverse strategy to meet partners’ needs across industry and academia. The teams are exploring closer integration between Latent Labs’ models, NVIDIA’s hardware roadmap and Nebius AI Cloud for model training and inference.
Sources
2 sourcesWhy AI Medical Research Needs Vast Computing Power and Where Nebius AI Cloud Fits In - Beyond Longevity
14 Oct 2026 · beyond-longevity.co.uk · Web page
A Nebius representative says Latent Labs used H100 GPUs for model training and tested Blackwell GPUs with Nebius, reporting a fourfold increase in training-cluster performance.
Open original sourceCompany context
latentlabs.comLatent Labs develops generative AI models and a browser-based platform for protein design, serving academic researchers, biotechnology companies and pharmaceutical teams. Its Latent-X1 and Latent-X2 models generate protein binders, including antibodies, macrocyclic peptides and mini-binder proteins. Latent-Y adds an AI agent that takes written research goals or scientific publications and coordinates target research, candidate generation, computational validation and refinement. The platform offers approved researchers free daily designs and paid additional credits, while enterprise partnerships support commercial drug discovery programs.
Latent LabsDocumented financing · private company
The company reported $50M in total funding; $40M of that was this Series A.
Recent updates
2 updatesLatent Labs opens Latent-Y to researchers worldwide
Approved researchers can use the drug-design agent through a free daily quota, with paid credits for larger campaigns.
Latent Labs releaseLatent Labs launches Latent-Y drug design agent
Latent Labs launched Latent-Y, an AI agent for therapeutic antibody design from a text prompt.
Latent Labs announcement